LCRF Scientific Advisory Board member Karen L. Reckamp, MD, explained the significance of the final results of the phase 1/2 and phase 2 ALTA trials in ALK-positive non–small cell lung cancer (NSCLC).
During the 2021 ASCO Annual Meeting in June, the final results of the ALTA trials showed sustained long-term activity with brigatinib (Alunbrig®) in patients with ALK-positive, crizotinib-resistant NSCLC.